Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Free Cash Flow (2023 - 2025)

Upstream Bio has reported Free Cash Flow over the past 3 years, most recently at -$30.7 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$30.7 million for Q4 2025, down 55.28% from a year ago — trailing twelve months through Dec 2025 was -$133.4 million (down 124.73% YoY), and the annual figure for FY2025 was -$133.4 million, down 123.58%.
  • Free Cash Flow for Q4 2025 was -$30.7 million at Upstream Bio, down from -$22.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for UPB hit a ceiling of -$8.0 million in Q2 2024 and a floor of -$41.2 million in Q1 2025.
  • Median Free Cash Flow over the past 3 years was -$19.8 million (2024), compared with a mean of -$23.2 million.
  • Biggest five-year swings in Free Cash Flow: dropped 22.89% in 2024 and later crashed 388.29% in 2025.
  • Upstream Bio's Free Cash Flow stood at -$16.1 million in 2023, then fell by 22.89% to -$19.8 million in 2024, then plummeted by 55.28% to -$30.7 million in 2025.
  • The last three reported values for Free Cash Flow were -$30.7 million (Q4 2025), -$22.2 million (Q3 2025), and -$39.2 million (Q2 2025) per Business Quant data.